Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study.
Biomed Pharmacother
; 145: 112243, 2022 Jan.
Article
in English
| MEDLINE | ID: covidwho-1432984
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
OBJECTIVE:
In this pilot clinical study, we report the beneficial effects of beta glucans derived from two strains AFO-202 and N-163 of a black yeast Aureobasidium pullulans on the biomarkers for cytokine storm and coagulopathy in COVID-19 patients.METHODS:
A total of 24 RT-PCR positive COVID-19 patients were recruited and randomly divided into three groups (Gr) Gr. 1 control (n = 8) - Standard treatment; Gr. 2 Standard treatment + AFO-202 beta glucan (n = 8); and Gr. 3, Standard treatment + combination of AFO-202 and N-163 beta glucans (n = 8) for 30 days.RESULTS:
There was no mortality or requirement of ventilation of the subjects in any of the groups. There was a decrease in D-Dimer values (751 ng/ml to 143.89 ng/ml) and IL-6 values (7.395-3.16 pg/ml) in Gr. 1 in 15 days but the levels increased to abnormal levels on day 30 (D-Dimer 202.5 ng/ml; IL-6 55.37 pg/ml); which steadily decreased up to day 30 in groups 2 (D-dimer 560.99 ng/dl to 79.615; IL-6 26.18-3.41 pg/ml) and 3 (D-dimer 1614 ng/dl to 164.25 ng/dl; IL-6 6.25-0.5 pg/ml). The same trend was observed with ESR. LCR and LeCR increased while NLR decreased significantly in Gr. 3. CD4 + and CD8 + T cell count showed relatively higher increase in Gr.3. There was no difference in CRP within the groups.CONCLUSION:
As these beta glucans are well known food supplements with a track record for safety, larger multi-centric clinical studies are recommended to validate their use as an adjunct in the management of COVID-19 and the ensuing long COVID-19 syndrome.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Fibrin Fibrinogen Degradation Products
/
Interleukin-6
/
Beta-Glucans
/
Cytokine Release Syndrome
/
Aureobasidium
/
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Diagnostic study
/
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
/
Traditional medicine
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Biomed Pharmacother
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS